Animal Health Solutions

Adequan ® Canine polysulfated glycosaminoglycan (PSGAG) solution 100 mg/mL in a 5 mL preserved Multiple dose vial for intramuscular use in dogs. Brief Summary: Prior to use please consult the product insert. Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Indications and Usage: Adequan Canine is recommended for intramuscular injection for the control of signs associated with non-infectious degenerative and/or traumatic arthritis of canine synovial joints. Efficacy: Efficacy of Adequan Canine was demonstrated in two studies, a laboratory study and a clinical field trial. Contraindications: PSGAG is a synthetic heparinoid; do not use in dogs with known or suspected bleeding disorders or in dogs showing hypersensitivity to PSGAG. Precautions: The safe use of Adequan Canine used in breeding, pregnant, or lactating dogs has not been evaluated. Use with caution in dogs with renal or hepatic impairment. Adverse Reactions: In the clinical efficacy trial, 24 dogs were treated with Adequan Canine twice weekly for 4 weeks. Possible adverse reactions were reported after 2.1% of the injections. These included transient pain at the injection site (1 incident), transient diarrhea (1 incident each in 2 dogs), and abnormal bleeding (1 incident). These effects were mild and self-limiting and did not require interruption of therapy. Post Approval Experience (2014): The following adverse events are based on voluntary, post-approval reporting. The signs reported are listed in decreasing order of reporting frequency: vomiting, anorexia, depression/lethargy, and diarrhea. In some cases, death has been reported. Warnings: Not for use in humans. Keep this and all medications out of reach of children. Dosage and Administration: Adequately clean and disinfect the stopper prior to entry with a sterile needle and syringe to decrease the possibility of post-injection bacterial infections. Use only sterile needles, and use each needle only once. Use in 28 days of first puncture and puncture a maximum of 10 times. This risk information is not comprehensive, visit adequancanine.com to obtain the FDA-approved product labeling. To report suspected adverse drug events, contact American Regent, Inc. at 1-888-354-4857. © 2023, American Regent, Inc. PP-AC-US-0597 Adequan and the Dog Head design are trademarks of American Regent, Inc. 8170 Half Pg.indd 1 8170 Half Pg.indd 1 7/6/23 10:34 AM 7/6/23 10:34 AM Firocoxib Chewable Tablets for Dogs For complete prescribing information, see full package insert. Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Indication: for the control of pain and inflammation associated with osteoarthritis and for the control of postoperative pain and inflammation associated with soft-tissue and orthopedic surgery in dogs. Warnings: For oral use in dogs only. Not for use in humans. Keep this and all medications out of the reach of children. Consult a physician in case of accidental ingestion by humans. Contraindications: Dogs with known hypersensitivity to firocoxib should not receive Firocoxib Chewable Tablets for Dogs. Precautions: This product cannot be accurately dosed in dogs less than 12.5 pounds in body weight. Consider appropriate washout times when switching from one NSAID to another or when switching from corticosteroid use to NSAID use. As a class, cyclooxygenase inhibitory NSAIDs may be associated with renal, gastrointestinal and hepatic toxicity. Sensitivity to drug-associated adverse events varies with individual patients. Dogs that have experienced adverse reactions from one NSAID may experience adverse reactions from another NSAID. Patients at greatest risk for adverse events are those that are dehydrated, on concomitant diuretic therapy, or those with renal, cardiovascular, and/or hepatic dysfunction. Concurrent administration of potentially nephrotoxic drugs should be carefully approached and monitored. NSAIDs may inhibit the prostaglandins that maintain normal homeostatic function. Such anti-prostaglandins effects may result in clinically significant disease that has not been previously diagnosed. Since NSAIDs possess the potential to produce gastrointestinal ulceration and/or gastrointestinal perforation, concomitant use of Firocoxib Chewable Tablets for Digs with other anti-inflammatory drugs, such as NSAIDs or corticosteroids, should be avoided. The concomitant use of protein bound drugs with Firocoxib Chewable Tablets for Dogs has not been studied in dogs. Commonly used protein-bound drugs include cardiac, anticonvulsant, and behavioral medications. The influence of concomitant drugs that may inhibit the metabolism of Firocoxib Chewable Tablets for Dogs has not been evaluated. Drug compatibility should be monitored in patients requiring adjunctive therapy. If additional pain medication is needed after the daily dose of Firocoxib Chewable Tablets for Dogs, a non-NSAID class on analgesic may be necessary. Appropriate monitoring procedures should be employed during surgical procedures. Anesthetic drugs may affect renal perfusion, approach concomitant use of anesthetics and NSAIDs cautiously. The use of parenteral fluids during surgery should be considered to decrease potential renal complications when using NSAIDs perioperatively. The safe use of Firocoxib Chewable Tablets for Digs in pregnant, lactating or breeding dogs has not been evaluated. To obtain full product information, request a Safety Data Sheet, or report suspected adverse events, please call 800-874-9764. Approved by FDA under ANADA # 200-751 Pegasus Laboratories, Inc. Dosage and Administration: For oral use in dogs only. The recommended dosage for Firocoxib Chewable Tablets for Dogs is 2.27 mg/lb (5.0 mg/kg) body weight once daily. Storage: Store at 20-25°C (68-77°F).

• Cover
• Online Pharmacy Maximze